Sera Prognostics, Inc. (SERA)

Market Cap	128.06M
Revenue (ttm)	77,000
Net Income (ttm)	-32.90M
Shares Out	37.66M
EPS (ttm)	-0.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,369
Open	3.340
Previous Close	3.350
Day's Range	3.300 - 3.430
52-Week Range	2.990 - 12.360
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2025

About SERA

Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction pane...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 15, 2021
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: SERA
• Website: https://www.sera.com

Financial Performance

In 2024, Sera Prognostics's revenue was $77,000, a decrease of -74.84% compared to the previous year's $306,000. Losses were -$32.90 million, -9.23% less than in 2023.